Loading data for ALDX — first visit, this takes a few seconds.

Aldeyra Therapeutics, Inc. (ALDX)

NasdaqCM: ALDX · 实时价格 · USD

1.48

+0.00 (0.00%)

收盘价： Sep 11, 2026, 3:59 PM

1.37

+2.24%

盘后: 7:30 PM

提醒

Alert

股价、关键数字和最新消息，都在这一页。

0.00% (1D)

买价	1.06
市值	80.8M
营收（TTM）	n/a
净利润（TTM）	-23.1M
	1.19
	-0.38
	n/a
	-4.87
市净率（TTM）	2.13
市销率（TTM）	0.00
财报日期	Nov 4, 2026

卖价	1.89
成交量	486,184
20日均量	1,251,688
开盘价	1.47
前收盘价	1.48
日内区间	1.46 - 1.49
52周区间	1.07 - 5.93
分析师	n/a
目标价	n/a
分红	n/a
除息日	n/a

关于 ALDX

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. T...

[阅读更多]

行业 Biotechnology

板块 Healthcare

上市日期 May 2, 2014

员工人数 6

交易所 NasdaqCM

股票代码 ALDX

官网 https://www.aldeyra.com

公司完整简介

财务表现

2025年，Aldeyra Therapeutics的营收为0，较上一年的0增长undefined%。净利润为-33.85M，下降-39.4%。

财务报表

财报意外

Aldeyra Therapeutics 已于 Aug 6, 2026 发布季度财报：

营收为 $0 低于预期 $0, ， NaN% 同比增长.
每股收益为 -0.09 低于预期 -0.01, ， 43.75% 同比增长.

下次财报发布时间

Aldeyra Therapeutics, Inc. 的下次财报预计于 Nov 4, 2026, 盘中。
分析师预计营收为 ... 升级

股价变动原因

新闻

5天前 · Zacks

CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?

Capricor shares jump in a month as positive phase III data and renewed FDA engagement revive hopes for deramiocel approval in DMD.

1周前 · Zacks

Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?

KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.

1周前 · Zacks

FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis

FDA accepts United Therapeutics' Tyvaso sNDA for an IPF label expansion, backed by TETON data showing improved lung function and reduced clinical worsening.

1周前 · Zacks

RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals

Ultragenyx plunges 46% after its phase III Angelman syndrome study fails to achieve key efficacy goals, putting apazunersen's future in question.

1周前 · Zacks

Here's Why You Should Add RNTX Stock to Your Portfolio Now

Rein Therapeutics advances LTI-03 in IPF. RENEW enrollment tops 25%, with interim data expected in the fourth quarter of 2026.

第 1 页，共 2 页

Aldeyra Therapeutics, Inc. (ALDX)